About
Newsroom
Key facts for journalists and others writing about the programme, how we report progress, and how we correct mistakes.
Press kit
About us
NWPharmaTech Ltd is a UK company developing NWPT-SM32300, an investigational oral cannabidiol medicine, for people at clinical high risk of psychosis. A Phase 1 study in healthy volunteers (NCT07186283) was completed on 10 December 2025; a Phase 2B study is planned. NWPT-SM32300 is not approved for any use and its effectiveness is unproven.
| Company | NWPharmaTech Ltd, company number 13572461, England and Wales |
|---|---|
| Investigational medicine | NWPT-SM32300: 300 mg oral softgel capsule of highly purified cannabidiol |
| Regulatory status | investigational; not approved by any medicines regulator for any use |
| Completed study | Phase 1, 14 healthy adult volunteers aged 18 to 55; NCT07186283, ISRCTN25163383; completed 10 December 2025 |
| Planned study | Phase 2B in people at clinical high risk of psychosis: Planned. Not recruiting. |
| Media contact | +44 20 3693 3791 (head office) |
Progress
Dated events are listed on the updates page, and study milestones with their sources on the study page. No programme reports have been published.
Corrections log
- 26 September 2026 — transition to psychosis (Salazar de Pablo et al., 2021, JAMA Psychiatry). The one-in-four figure (25% within three years) is the paper’s pooled estimate. It had been labelled a Kaplan–Meier estimate on the home page, the family guide, this evidence library and the clinical-need explainer. The paper’s separate Kaplan–Meier series (8% at six months, 14% at one year, 20% at two years, 27% at three years and 35% at ten years) is now shown as a separate analysis, and the two are not combined. The older pooled averages of Fusar-Poli et al., 2012 are unchanged. Details: evidence library.